A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)
NCT03383263 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2021-08-30
Summary
The objective of this study is to assess persistence, adherence and changes in disease activity in the children population of juvenile arthritis patients treated with adalimumab (HUMIRA®) in the routine clinical settings in the Russian Federation.
Conditions
- Polyarticular Juvenile Arthritis
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
AbbVie Inc. · AbbVie
Eligibility
- Min Age
- 2 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-05-04
- Primary Completion
- 2020-09-14
- Completion
- 2020-09-14
Countries
- Russia
Study Locations
More Related Trials
-
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
NCT02480153 ·Status: COMPLETED ·Phase: PHASE3
-
A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece
NCT01086033 ·Status: COMPLETED
-
Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate
NCT04042792 ·Status: COMPLETED
-
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT01844518 ·Status: COMPLETED ·Phase: PHASE3
-
Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers
NCT02395055 ·Status: COMPLETED ·Phase: PHASE1
-
Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA
NCT02322723 ·Status: WITHDRAWN
-
A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis
NCT03789292 ·Status: COMPLETED ·Phase: PHASE3
-
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
NCT03339102 ·Status: COMPLETED
-
A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients
NCT02405780 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
NCT01078090 ·Status: COMPLETED
-
Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis
NCT02919761 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))
NCT02237729 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
NCT01077258 ·Status: COMPLETED
-
Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis
NCT00233558 ·Status: TERMINATED ·Phase: PHASE4
-
Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis
NCT01163318 ·Status: COMPLETED
-
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
NCT04230213 ·Status: COMPLETED ·Phase: PHASE3
-
Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)
NCT01382160 ·Status: COMPLETED ·Phase: PHASE4
-
Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))
NCT01163292 ·Status: COMPLETED
-
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
NCT02019472 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
NCT03357939 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
NCT07181694 ·Status: RECRUITING ·Phase: PHASE1
-
To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects
NCT03970824 ·Status: COMPLETED ·Phase: PHASE1
-
Optimization of Treatment With Adalimumab (Humira)
NCT01585064 ·Status: COMPLETED
-
Post-marketing Observational Study in Subjects With Rheumatoid Arthritis
NCT00234884 ·Status: COMPLETED
-
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
NCT02916017 ·Status: COMPLETED